Arnaud Scherpereel

Arnaud Scherpereel

Lille, 59037, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 148 publications

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 10, 2026

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2026

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 24, 2026

Corrigendum to 'Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact' [Journal of Thoracic Oncology Volume 21 Issue 1 (2026) 41-76].

Corrigendum to 'Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact' [Journal of Thoracic Oncology Volume 21 Issue 1 (2026) 41-76].

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 13, 2026

Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial.

Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 23, 2025

Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.

Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 17, 2025

Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.

Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 13, 2025

Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.

Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 09, 2025

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.

Journal: Therapeutic advances in medical oncology

Published: August 13, 2025

Life-threatening immune-related adverse events in the intensive care unit: a narrative review.

Life-threatening immune-related adverse events in the intensive care unit: a narrative review.

Journal: Intensive care medicine

Published: July 06, 2025

MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.

MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.

Journal: Translational oncology

Published: June 09, 2025

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers.

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers.

Journal: Oncoimmunology

Published: April 07, 2025

Showing 1-12 of 148

Last Updated: 09/26/2026